Molecule News and Research

RSS

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University School of Medicine in St. Louis have created a potential new type of anticancer therapy with the potential to target a wide range of tumors. This work was reported in the Journal of Clinical Investigation.

7 Sep 2009

Researchers discover the causes for the severity of RSV illness

Approximately one-half of all infants are infected with the respiratory syncytial virus (RSV) during the first year of life, and almost all children have been infected at least once by the time they reach their second birthday. Researchers at West Virginia University have discovered what makes RSV such a severe and persistent illness.

4 Sep 2009

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

ROS in cells contributes to aging

With all the hype about beneficial antioxidants in everything from face cream to cereal bars, you'd think their targets---oxygen radicals---must be up to no good. It's true, the buildup of oxygen radicals and other reactive oxygen species (ROS) in cells contributes to aging and possibly to diseases such as cancer and Alzheimer's.

3 Sep 2009

Second-quarter 2009 operating highlights announced by Helicos Biosciences

Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its operating highlights for the quarter ended June 30, 2009 and other recent developments following the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2009.

3 Sep 2009

Ten of ChemBridge's screening libraries available through CDD database

ChemBridge Corporation, a leading discovery chemistry company offering an extensive portfolio of discovery chemistry products and contract research services, has now made ten of their most popular screening libraries available to researchers via the Collaborative Drug Discovery (CDD) Public Access database.

3 Sep 2009

P2Y2 to be included in the intellectual property sale auction

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction.

3 Sep 2009

New probe for identifying chemical process affected proteins functions like GPS

Scientists in Michigan are reporting the development of a powerful new probe for identifying proteins affected by a key chemical process important in aging and disease. The probe works like a GPS or navigation system for finding these proteins in cells. It could lead to new insights into disease processes and identify new targets for disease treatments, the researchers say. Their study is scheduled for the Sept. 18 issue of ACS Chemical Biology, a monthly journal.

3 Sep 2009

Mosquito screens prevent malaria

Trials of a screen-based malaria prevention programme in 500 homes in The Gambia, Africa, have led to a 50 per cent reduction in malaria transmission and anaemia in children. A child dies from malaria in Africa every 30 seconds and infection can lead to an increased risk of anaemia, which can also prove fatal. Yet to date, screens have often been ignored in favour of using drugs and insecticides.

3 Sep 2009

Researchers to analyse nanoparticles

Researchers at Swansea University's Centre for NanoHealth have been awarded £1 million by the Research Councils' Nanoscience through Engineering to Application cross-council programme, led by the Engineering and Physical Science Research Council (EPSRC), to analyse the levels at which nanoparticles can be deemed safe within cells.

3 Sep 2009

Third-quarter fiscal 2009 results announced by Synovis Life Technologies

Synovis Life Technologies Reports Record Revenue Of $15 Million For The Third Quarter Of Fiscal 2009

2 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

2 Sep 2009

Pathogenic microbes can suppress immune system in newborns

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

2 Sep 2009

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir’s existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.

1 Sep 2009

Nuevolution partners with Novartis for drug research

Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Novartis.

31 Aug 2009

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Geneuity Clinical Research Services announces the recent validation and use in clinical trials of two human biomarker assays that play a key role in the early detection of kidney damage.

29 Aug 2009

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.

28 Aug 2009